PURPOSE: Ovarian carcinoma in most instances is diagnosed in an advanced stage which cannot be cured by surgical tumor debulking alone. Standard adjuvant chemotherapy usually follows surgical procedures. Yet, few reliable predictive tissue markers exist for the response of ovarian carcinoma to chemotherapy. In this study, we evaluated the predictive value of IL-17- and FOXP3-positive tumor immune cell infiltration (TICI) for response to chemotherapy in ovarian carcinoma. METHODS: Formalin fixed and paraffin embedded biopsies of mostly high-grade primary serous ovarian carcinomas and their matched recurrences were immunostained with IL-17 and FOXP3 on a tissue microarray. Chemoresistance was defined as tumor recurrence within 6 months of the completion of platinum-based chemotherapy. In 94 and 90 biopsies, conclusive data for IL-17 and FOXP3 were available, respectively. RESULTS: IL-17, but not FOXP3-positive TICI, displayed a significantly higher density in biopsies of chemosensitive tumors (p = 0.01). No significant difference in the expression of IL-17 and FOXP3 TICI was observed in all paired primary and recurrent biopsies without respect to chemoresponse (p = 0.77 and p = 0.87, respectively). However, significantly more IL-17-positive recurrences were encountered in the group of patients with chemosensitive tumors (p = 0.008). CONCLUSIONS: High IL-17-positive TICI is indicative for response to chemotherapy in ovarian carcinoma. Higher frequency of IL-17-positive TICI might persist in recurrent tumor tissues of chemosensitive biopsies, suggesting repetitive platinum-based chemotherapy as an appropriate therapy for patients with IL-17-positive recurrences.
PURPOSE:Ovarian carcinoma in most instances is diagnosed in an advanced stage which cannot be cured by surgical tumor debulking alone. Standard adjuvant chemotherapy usually follows surgical procedures. Yet, few reliable predictive tissue markers exist for the response of ovarian carcinoma to chemotherapy. In this study, we evaluated the predictive value of IL-17- and FOXP3-positive tumor immune cell infiltration (TICI) for response to chemotherapy in ovarian carcinoma. METHODS:Formalin fixed and paraffin embedded biopsies of mostly high-grade primary serous ovarian carcinomas and their matched recurrences were immunostained with IL-17 and FOXP3 on a tissue microarray. Chemoresistance was defined as tumor recurrence within 6 months of the completion of platinum-based chemotherapy. In 94 and 90 biopsies, conclusive data for IL-17 and FOXP3 were available, respectively. RESULTS:IL-17, but not FOXP3-positive TICI, displayed a significantly higher density in biopsies of chemosensitive tumors (p = 0.01). No significant difference in the expression of IL-17 and FOXP3 TICI was observed in all paired primary and recurrent biopsies without respect to chemoresponse (p = 0.77 and p = 0.87, respectively). However, significantly more IL-17-positive recurrences were encountered in the group of patients with chemosensitive tumors (p = 0.008). CONCLUSIONS: High IL-17-positive TICI is indicative for response to chemotherapy in ovarian carcinoma. Higher frequency of IL-17-positive TICI might persist in recurrent tumor tissues of chemosensitive biopsies, suggesting repetitive platinum-based chemotherapy as an appropriate therapy for patients with IL-17-positive recurrences.
Authors: Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth Journal: Clin Cancer Res Date: 2005-12-01 Impact factor: 12.531
Authors: Esther M de Kruijf; Johanna G H van Nes; Anita Sajet; Quirijn R J G Tummers; Hein Putter; Susanne Osanto; Frank M Speetjens; Vincent T H B M Smit; Gerrit Jan Liefers; Cornelis J H van de Velde; Peter J K Kuppen Journal: Clin Cancer Res Date: 2010-02-09 Impact factor: 12.531
Authors: Alberto Posabella; Philipp Köhn; Alexandros Lalos; Alexander Wilhelm; Robert Mechera; Savas Soysal; Simone Muenst; Uwe Güth; Sylvia Stadlmann; Luigi Terracciano; Raoul A Droeser; Jasmin Zeindler; Gad Singer Journal: J Cancer Res Clin Oncol Date: 2019-12-18 Impact factor: 4.553
Authors: Simone Punt; Jessica M Langenhoff; H Putter; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova Journal: Oncoimmunology Date: 2015-03-06 Impact factor: 8.110
Authors: Raoul A Droeser; Robert Mechera; Silvio Däster; Benjamin Weixler; Marko Kraljević; Tarik Delko; Uwe Güth; Sylvia Stadlmann; Luigi Terracciano; Gad Singer Journal: BMC Cancer Date: 2016-08-17 Impact factor: 4.430